A study investigated the use of a fut variant-based CA19-9 tumor marker gene test to assess the outcome of pancreatic cancer surgery. The test showed that higher preoperative CA19-9 levels were associated with recurrence and mortality in patients with higher fut groups, but not in lower fut groups. CA19-9 levels after neoadjuvant therapy and normalization based on fut group were found to be predictors of response to therapy and early recurrence. The gene test modestly improved the prognostic performance of CA19-9.
Journal Article by Ando Y, Dbouk M (…) Goggins M et 9 al. in Ann Surg Oncol
© 2024. Society of Surgical Oncology.